Extended-spectrum beta-lactamase (ESBL) enzymes have become abundant. They are not only able to hydrolyze penicillins but also newer, third-generation cephalosporins and monobactams. Limitations in antimicrobial therapies result from a multidrug-resistant (MDR) phenotype present in these bacteria, which are often additionally resistant against fluoroquinolones, aminoglycosides, and other classes of antimicrobials ([@CIT0001]). ESBL-producing *Escherichia coli* in humans, livestock, wildlife, and in non-clinical ([@CIT0002]--[@CIT0004]) and clinical isolates of companion animals originating from soft tissue, enteric, or urinary tract infections ([@CIT0005]) are well documented. Limited data, however, are available concerning the rate of these bacteria in dog feces outside of clinical settings worldwide ([@CIT0006]) as well as regarding a possible transmission of multiresistant bacteria from veterinary clinics into the environment. Berlin is the city in Germany with the most dogs per inhabitant ([@CIT0007]). The dog often lives in close contact with its human companion and sometimes shares home and bed ([@CIT0008], [@CIT0009]) and routinely leaves excrement on streets and fields. It is highly interesting to what extent canine feces may carry zoonotic, multiresistant *E. coli* and its implications for transmission pathways in public health. Also, the keeping of dogs has been recently identified as a putative risk factor for ESBL secretion in owners ([@CIT0010]). The aim of this study was to provide a 'One Health' approach in estimating the rate of ESBL-producing *E. coli* in dog feces outside of clinical settings. The samples were collected on a publicly accessible veterinary campus with small-animal clinic in Berlin to assess a possible link between the clinic and the surrounding environment, acknowledging, however, that the proof of a direct epidemiological link would be difficult to establish. A likely contamination of the environment surrounding small-animal veterinary hospitals with multiresistant bacteria was previously demonstrated by Ghosh et al. ([@CIT0011]). In addition, samples were collected from adjacent residential neighborhoods of the veterinary faculty. This study detected high rates of ESBL-producing *E. coli* outside the clinical setting and discovered clonal strains from extra-clinical dog feces and clinical dog isolates.

Material and methods {#S0001}
====================

The samples were collected on a campus of the veterinary faculty and adjacent neighborhoods in the city of Berlin (Germany) within a 24-hour period in June 2013. The area (approximately 2.5 square kilometers) was divided into five equal sized districts. Individual fecal residues, presumably from dogs, were collected using 20 swabs from each district providing 100 total fecal samples. Data collection procedures called for there to be at least 10 meters of distance between the sampling sites and to collect only fresh appearing samples to avoid sampling the same animal more than once. Third-generation cephalosporin-resistant bacteria were isolated using cefotaxime (4 µg/ml)-containing CHROMagar™ plates and were confirmed as *E. coli* via classical biochemical methods including glucose fermentation (Kligler agar), lysin-indol-motility (LIM agar), and urea fermentation ([@CIT0012]). One putative ESBL-producing *E. coli* isolate per sample was further processed. Confirmatory testing (BD BBL^®^ Sensi-Disc \[Becton, Dickinson, Germany\]) using the control strain *K. pneumoniae* ATCC^®^700603 analyzed the occurrence of not only ESBL-producing strains but also putative AmpC-producing strains ([@CIT0013]). Additional resistances to ampicillin, amoxicillin--clavulanic acid, gentamicin, kanamycin, doxycycline, sulfonamide--trimethoprim, chloramphenicol, nalidixic acid (BD BBL^®^ Sensi-Disc \[Becton, Dickinson, Germany\]), and enrofloxacin (Bayer, Germany) were tested using agar disc diffusion testing according to the CLSI guidelines with the control strain *E. coli* ATCC^®^25922 ([@CIT0013]). Following DNA isolation, resistance genotyping of the strains was performed via DNA microarray (Alere technologies, Jena, Germany, Array strip^®^ *E. coli*) ([@CIT0014]). Hybridization results for *bla* ~CTX-M-like~, *bla* ~TEM-like~, *bla* ~OXA-like~, and plasmidic AmpC-genes like *bla* ~CMY-1~ were verified via polymerase chain reaction (PCR) and sequencing as described previously ([@CIT0015], [@CIT0016]). The phylogenetic group was determined using Structure 2.3.4 software based on the concatenated sequences of the seven housekeeping genes used for multilocus sequence typing (MLST) (University of Chicago \[<http://pritch.bsd.uchicago.edu/structure.html>\]). MLST determination was carried out as described previously ([@CIT0017]). Gene amplification and sequencing were performed using primers specified on the *E. coli* MLST website (University of Warwick \[<http://mlst.warwick.ac.uk/mlst/>\]). Sequences were analyzed with the software package Ridom SeqSphere 0.9.39 (Ridom website \[<http://www3.ridom.de/seqsphere>\]) and sequence types (STs) were computed automatically. Pulsed-field gel electrophoresis (PFGE) was used as recently described ([@CIT0015]) to detect clonally related extra-clinical ESBL-/putative AmpC-producing strains, to estimate the impact of double sampling and to compare the extra-clinical samples to 11 previously confirmed ESBL/putative AmpC-producing *E. coli* isolates from diseased dogs, which were collected in the small-animal clinic 2 months before and 2 months following the extra-clinical sampling time point. This time period was chosen in order to increase the odds of finding clinical strains with similar macrorestriction patterns compared to those isolated from the extra-clinical dog feces considering the low overall detection of ESBL-producing *E. coli* in the clinic. Samples collected from diseased dogs included wound tissue, feces, and urine.

Results {#S0002}
=======

In an area of approximately 2.5 square kilometers, 16 of 100 extra-clinical fecal samples revealed cefotaxime-resistant *E. coli*, 12 of which were ESBL producers and four putative AmpC producers. PFGE detected clones of two ESBL-producing *E. coli* strains (which were removed from the analysis), resulting in 10 (10%) ESBL-producing, four (4%) putative AmpC-producing, and overall 14 (14%) non-clonal strains. At least one ESBL-producing *E. coli* was found in all five districts, with no differential repartition. Thirteen strains (including ESBL- and putative AmpC-producers) were resistant to three or more than three antimicrobial classes, thus showing a multiresistant phenotype. Resistance to ampicillin (14/14), amoxicillin--clavulanic acid (10/14), gentamicin (9/14), kanamycin (12/14), doxycycline (13/14), and sulfamethoxazole--trimethoprim (12/14) was common, but chloramphenicol (4/14), nalidixic acid (7/14) and enrofloxacin-resistance (5/14) also occurred ([Fig. 1](#F0001){ref-type="fig"}a). Resistance genotyping using DNA microarray accorded mostly with the phenotypic results (see [Fig. 1](#F0001){ref-type="fig"}a for details). All ESBL-producing strains (10/10) showed positive signals for the *bla* ~CTX-M-group-1~ probe, which was confirmed by sequencing (*bla* ~CTX-M-1~ \[5/10\], *bla* ~CTX-M-15~ \[5/10\]). All putative AmpC-producing strains (4/4) were initially positive for the *bla* ~MOX-CMY-9~ probe (a class C ESBL-precursor) and additionally harbored *bla* ~CTX-M-1~, but CMY-1 could only be verified for one strain (IMT31346) with PCR. Other AmpC genes including *bla* ~FOX~, *bla* ~MOX~, and *bla* ~ACT~ were negative ([@CIT0016]). Analysis also detected *bla* ~TEM-1~ (7/14) and *bla* ~OXA-1~ (5/14). Non-beta-lactam resistance genes were *tetA/B* (13/14)*, sul1/2* (13/14)*, strA/B* (7/14), *catA1/B3/B8* (9/14), as well as *aadA4* (8/14)*, aac(6')-II* (5/14)*, dfrA7/17/19/21* (12/14), and *qnrS* (1/14) ([Fig. 1](#F0001){ref-type="fig"}a).

![(a) Phenotypic and genotypic typing results of ESBL- and AmpC-producing *E. coli* isolates based on a dendrogram (\>*Xba*I-generated PFGE profiles after exclusion of double clones). Software: BioNumerics 6.6, Applied Maths, Belgium, cluster analysis of dice similarity indices based on the unweighted pair group method with arithmetic mean (UPGMA). (b) Comparison of clones from clinical dog isolates and extra-clinical fecal samples.\
CEF: cefotaxime; AMP: ampicillin; AMC: amoxicillin--clavulanic acid; GEN: gentamicin; KAN: kanamycin; DOX: doxycycline; SXT: sulfamethoxazole--trimethoprim; CAP: chloramphenicol; NAL: nalidixic acid; ENRO: enrofloxacin; R: resistant; I: intermediate.](IEE-5-25334-g001){#F0001}

The 10 ESBL-producing strains belonged mostly to phylogenetic group B1 (7/10), three strains belonged to groups D, A, and hybrid group AxB1 (1/10 each). The putative AmpC-producers belonged to ECOR groups B1 (2/4), B2 (1/4), and D (1/4) ([Fig. 1](#F0001){ref-type="fig"}a). MLST revealed seven different STs (e.g. ST410 and ST10) among ESBL-producers and four different ones among putative AmpC-producing isolates (see [Fig. 1](#F0001){ref-type="fig"}a for details).

PFGE revealed one environmental strain (IMT31359), which showed the same macrorestriction pattern as one clinical isolate (IMT31487) and another one (IMT31356), which was identical to three clonal isolates (IMT31286, IMT31333, and IMT31711) from individual dogs treated in the small-animal clinic ([Fig. 1](#F0001){ref-type="fig"}b).

Discussion {#S0003}
==========

A substantial number (14%) of the extra-clinical dog feces tested harbored ESBL/putative AmpC-producing *E. coli* with additional resistances to other antimicrobial classes. Despite their origin of different sampling districts, clones of two strains were removed from the analysis to reduce the bias of sampling the feces of the same dog. It is also possible, however, that the same clones occur in different animals. The appearance of identical clinical strains (IMT31286, IMT31333, and IMT31711) collected from different samples from different dogs at different time points underlines the success of certain clones in this clinical setting. Finding that same clone (IMT31356) outside the clinic supports the hypothesis of clinical-isolate transmission into the environment, possibly through one of the infected dogs or asymptomatically colonized animals. Interestingly, the corresponding clinical clones do not originate from gastrointestinal infections, but from urinary-tract and wound infections, demonstrating the clinical relevance of certain clones. Certain genetic resistance determinants found in the samples collected in this study, namely *bla* ~CTX-M-1~ and *bla* ~CTX-M-15~, have recently been reported to be highly prevalent types of ESBL-colonizers in the healthy community in Bavaria (Germany) ([@CIT0018]) and also in non-clinical and clinical samples from humans and companion animals in Europe ([@CIT0002], [@CIT0004], [@CIT0005], [@CIT0019]). Besides these gene types, detected STs including ST410 and ST224 are typically ESBL-associated STs, which have been frequently found in human medicine ([@CIT0005]).

Although this pilot study faces epidemiological limitations due to a restricted sample size and non-identical sampling time procedures, the reservoir role of dog feces, which contain ESBL-producing *E. coli*, must not be underestimated.

The rate detected in this study reflects a slightly higher percentage of ESBL-/putative AmpC-producing *E. coli* than that of human isolates outside of hospital environments (3--10%) ([@CIT0018], [@CIT0020], [@CIT0021]). The results might be influenced by the presence of the small-animal clinic in this area, which treats patients with antibiotics, thus selecting for resistance genes and therefore giving one explanation for high carriage of resistant bacteria in dogs taken for a walk on the campus. In addition, previous studies discussed a wash out of multiresistant bacteria from human and veterinary hospitals into the environment ([@CIT0011], [@CIT0022], [@CIT0023]). However, dog owners visiting the clinic do not usually walk their dog as far as the adjoining areas where half the samples were collected, and other studies investigating healthy pets in Tunisia found comparable numbers of ESBL producers ([@CIT0003]. Regardless, it is worth investigating further the extent to which dog feces in other public urban areas of Berlin, in the adjacent neighborhoods of veterinary clinics, and cities worldwide, contain multiresistant *E. coli*.

Conclusion {#S0004}
==========

To best of the authors' knowledge, this is the first study estimating the rate of ESBL-/putative AmpC-producing *E. coli*, which have been isolated from environmental dog feces, and comparing these to isolates from a nearby small-animal clinic. As dogs often live close to humans and their zoonotic role as potential carriers of multiresistant strains should not be underestimated, their feces as a mechanism for transmission in environmental settings, particularly in close proximity to veterinary clinics, must be acknowledged and better understood. Dog owners in general but especially those of diseased dogs should be educated to remove the pet's feces immediately as other dogs' sniffing behavior might contribute to the zoonotic and environmental spread of ESBL-producing bacteria.

Despite the limits of this study's generalizability, it follows an integrated, 'One Health' approach that might serve as a model for future cross-cutting collaborations as well as opportunities for expanded epidemiological research and next-generation sequencing applications in the field of multiresistant bacteria.
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